Experimental immune therapy for stubborn anemia shows early promise but trial stalls

This early-phase trial tested whether low doses of interleukin-2 (IL-2), a protein that helps regulate the immune system, could help people with warm autoimmune hemolytic anemia (wAHAI) whose disease did not improve with standard steroid treatment. The study planned to give four short courses of IL-2 injections over nine weeks and measure changes in certain immune cells and signs of red blood cell breakdown. However, the trial was terminated after enrolling only 2 participants, so no meaningful conclusions can be drawn about safety or effectiveness.